Telithromycin

Nature Reviews Drug Discovery

Volumn 3, Issue 9, 2004, Pages 733-734

  Raja, Aarti ^a   Lebbos, John ^a   Kirkpatrick, Peter ^b  

^a Decision Resources Inc   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

AMINOGLYCOSIDE ANTIBIOTIC AGENT; AZITHROMYCIN; BETA LACTAM ANTIBIOTIC; CARBAPENEM DERIVATIVE; CEPHALOSPORIN DERIVATIVE; CLARITHROMYCIN; ERYTHROMYCIN; GARENOXACIN; GATIFLOXACIN; GEMIFLOXACIN; LEVOFLOXACIN; MACROLIDE; MOXIFLOXACIN; OXAZOLIDINONE DERIVATIVE; PENICILLIN DERIVATIVE; POLYPEPTIDE ANTIBIOTIC AGENT; QUINOLINE DERIVED ANTIINFECTIVE AGENT; STREPTOGRAMIN DERIVATIVE; TELITHROMYCIN; TETRACYCLINE DERIVATIVE;

ANTIBACTERIAL ACTIVITY; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; CHRONIC BRONCHITIS; CLINICAL TRIAL; COMMUNITY ACQUIRED PNEUMONIA; DRUG APPROVAL; DRUG EFFICACY; DRUG INDICATION; DRUG MARKETING; DRUG PROTEIN BINDING; DRUG SAFETY; FOOD AND DRUG ADMINISTRATION; HAEMOPHILUS INFLUENZAE; HUMAN; MORAXELLA CATARRHALIS; NONHUMAN; NOTE; PRIORITY JOURNAL; RESPIRATORY TRACT INFECTION; SINUSITIS; STREPTOCOCCUS PNEUMONIA; STREPTOCOCCUS PNEUMONIAE; STRUCTURE ACTIVITY RELATION;

ANTI-BACTERIAL AGENTS; BACTERIAL INFECTIONS; CLINICAL TRIALS; DRUG APPROVAL; DRUG DESIGN; DRUG RESISTANCE, BACTERIAL; FLAVIN-ADENINE DINUCLEOTIDE; HUMANS; KETOLIDES; MACROLIDES; UNITED STATES;

EID: 4544353744     PISSN: 14741776     EISSN: None     Source Type: Journal    
DOI: 10.1038/nrd1502     Document Type: Note

References (8)

1. Nilius, A. M. & Ma. Z. Ketolides: the future of the macrolides? Curr. Opin. Pharmacol. 2, 493-500 (2002).
2. Schlünzen, F. et al. Structural basis for the interaction of antibiotics with the peptidyl transferase centre in eubacteria. Nature 413, 814-821 (2001).
3. Agouridas, C. et al. Synthesis and antibacterial activity of ketolides (6-O-methyl-3-oxoerythromycin derivatives): a new class of antibacterials highly potent against macrolide-resistant and -susceptible respiratory pathogens. J. Med. Chem. 41, 4080-4100 (1998).
4. Denis, A. et al. Synthesis and antibacterial activity of HMR 3647 a new ketolide highly potent against erythromycin-resistant and susceptible pathogens. Bioorg. Med. Chem. Lett. 9, 3075-3080 (1999).
5. FDA drug approvals list [online], http://www.fda.gov/cder/foi/label/2004/21144_ketek_lbl.pdf (2004).
6. Reinert, R. R. Clinical efficacy of ketolides in the treatment of respiratory tract infections. J. Antimicrob. Chemother. 53, 918-927 (2004).
7. World Health Report. 2003. [online], http://www.who.int/whr/2003/en/ (2003).
8. Doern, G. V. & Brown, S. D. Antimicrobial susceptibility among community-acquired respiratory tract pathogens in the USA: data from PROTEKT US 2000-01. J. Infect. 48, 56-65 (2004).